Lixte Reports Positive Activity of Tumor Drugs in Mouse Model of Cancer
Posted on: Tuesday, 12 August 2008, 03:01 CDT
Lixte Biotechnology Holdings has announced that lead compounds from each of two different types of drugs being developed as potential treatment for specific types of brain cancers have activity against human pancreatic cancers in a mouse model.
John Kovach, president and CEO of Lixte, said: "Lixte previously reported that lead compounds from each of two different classes of pharmacologic agents have significant inhibitory activity against several types of human cancers in the test tube and against brain cancers in animal models. We have now found that two different lead compounds also have statistically significant activity against human pancreatic cancer cells growing in mice.
"These are early studies and there is no evidence that these drugs are able to eliminate pancreatic cancers but rather slow their growth. We are encouraged, however, that two classes of our drugs have activity against this devastating cancer in addition to glioblastoma multiforme, the most common and most malignant form of brain cancer."
Source: Datamonitor
Related Articles
- Pancreatic Cancer: Know it. Fight it. End it.
- Pancreatic Cancer Action Network Launches Platinum Visa Credit Card to Raise Awareness for the Fourth Leading Cause of Cancer Death in the United States
- The Pancreatic Cancer Action Network Announces Its 2008 Research Grant Awards Totaling Over $1 Million in New Research Funding
- BiPar Finds Effective Cancer Therapy to Inhibit Pancreatic Cancer
- The Challenge of Pancreatic Cancer and Men With Breast Cancer; This Week on Your Cancer Today(TM)
- Bystander Effect of Introgen's INGN 241 Increases Cancer-Killing Activity in Breast Cancer Cells
- Pancreatic Cancer Latest Target in Peer to Peer Computer Campaign
- pSivida Expands Market for Lead Cancer Product BrachySil-TM- ; Pancreatic Cancer - Significant Unmet Clinical Need
- Abbott Northwestern's Virginia Piper Cancer Institute Joins the Pancreatic Cancer Research Team
- Dietary Intake of Lycopene Is Associated With Reduced Pancreatic Cancer Risk1
 |
 |
User Comments (0)
RSS Feeds